Joseph Verbalis
Endocrinology, Diabetes & Metabolism · Washington, DCNPI 1194724047
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.6%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Otsuka Pharmaceutical Co., Ltd. at 50.4% of the total. Reporting peaked in 2021 at $9,317 and has fallen 81.3% since, to $1,740 in 2024. Among endocrinology, diabetes & metabolism clinicians in DC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 27 payments — averaging $907.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka Pharmaceutical Co., Ltd.$12K
- Ferring Pharmaceuticals Inc.$7K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$3K
- EUSA Pharma (US) LLC$2K
- Novo Nordisk$250
- Corcept Therapeutics$231
What the payments were for
- Consulting fees$8,37334%
- Speaking & faculty fees$14,61060%
- Travel & lodging$6563%
- Food & beverage$8283%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka Pharmaceutical Co., Ltd. | 7 | $12,335 |
| Ferring Pharmaceuticals Inc. | 10 | $6,780 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $2,627 |
| EUSA Pharma (US) LLC | 1 | $2,275 |
| Novo Nordisk | 3 | $250 |
| Corcept Therapeutics | 2 | $231 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,498 in reported general payments places this provider in the 90th percentile of 44 endocrinology, diabetes & metabolism providers in District of Columbia.
See all endocrinology, diabetes & metabolism providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Testosterone | 21 | $1,025 |
| Levothyroxine Sodium | 16 | $710 |
| Cabergoline | 19 | $582 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Washington
- Natasa Janicic-KahricWashington$121K
- Diala El-MaoucheWashington$99K
- Abbas MotazediWashington$31K
- Meeta SharmaWashington$25K
- Mark SklarWashington$14K
- Sabyasachi SenWashington$12K
- Rui LuWashington$12K
- Qudsia HussainWashington$9K
- Jerold ShareWashington$7K
- Leonard WartofskyWashington$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.